SCHEMBL12379611

SCHEMBL12379611

Cc1sc(C(=O)NC2CCCC[C@H]2N)nc1-c1cnn2cc(-c3cnn(C)c3)ccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MARK3 P27448 9/20 0.59
IRAK4 Q9NWZ3 6/20 0.53
SYK P43405 3/20 0.53
GSK3B P49841 2/20 0.53
DYRK1A Q13627 2/20 0.53
SGK1 O00141 1/20 0.53
PIK3CD O00329 1/20 0.53
CHEK1 O14757 1/20 0.53
MAPK13 O15264 1/20 0.53
PDPK1 O15530 1/20 0.53
NUAK1 O60285 1/20 0.53
CCNT1 O60563 1/20 0.53
JAK2 O60674 1/20 0.53
ROCK2 O75116 1/20 0.53
CHEK2 O96017 1/20 0.53
ABL1 P00519 1/20 0.53
EGFR P00533 1/20 0.53
RAF1 P04049 1/20 0.53
ERBB2 P04626 1/20 0.53
NTRK1 P04629 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2288775 1.00 MARK3 (0.59) MARK3IRAK4SYKGSK3BDYRK1A
SCHEMBL2288768 1.00 MARK3 (0.59) MARK3IRAK4SYKGSK3BDYRK1A
SCHEMBL2288772 1.00 MARK3 (0.59) MARK3IRAK4SYKGSK3BDYRK1A
SCHEMBL2293443 0.86 MARK3 (0.51) MARK3IRAK4SYKGSK3BDYRK1A
SCHEMBL12379607 0.84 MARK3 (0.47) MARK3IRAK4SYKGSK3BDYRK1A
SCHEMBL15103726 0.82 SYK (0.45) MARK3IRAK4SYKGSK3BDYRK1A
SCHEMBL2290601 0.75 MAPK1 (0.45) KITMAPK1
SCHEMBL2291527 0.75 MAPK1 (0.49) KITMAPK1
SCHEMBL2293385 0.75 HDAC4 (0.41) MARK3IRAK4SYKGSK3BDYRK1A
SCHEMBL2295778 0.75 HDAC4 (0.41) MARK3IRAK4SYKGSK3BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518911-B2 Pyrazolo[1,5-a]pyridines as MARK inhibitors MERCK SHARP & DOHME CORP. (US) 2013-08-27 US disclosed
US-20110195933-A1 PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS MERCK SHARP & DOHME LLC 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195933-A1 PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS MARK3, MARK4, MARK1 MARK3 1/4885IRAK4 975/4885SYK 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.